SteadyMed Ltd. (NASDAQ:STDY) is set to post its quarterly earnings results before the market opens on Monday, November 13th. Analysts expect SteadyMed to post earnings of ($0.34) per share for the quarter.

SteadyMed (NASDAQ:STDY) last announced its quarterly earnings results on Friday, August 11th. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.01). SteadyMed had a negative return on equity of 226.48% and a negative net margin of 3,179.76%. The company had revenue of $0.32 million during the quarter, compared to analyst estimates of $0.26 million. On average, analysts expect SteadyMed to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Shares of SteadyMed Ltd. (NASDAQ STDY) opened at $3.15 on Monday. SteadyMed Ltd. has a 12-month low of $2.25 and a 12-month high of $9.70.

A number of analysts have weighed in on the company. ValuEngine cut SteadyMed from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Zacks Investment Research raised SteadyMed from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th.

ILLEGAL ACTIVITY WARNING: “SteadyMed Ltd. (STDY) Scheduled to Post Earnings on Monday” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at

SteadyMed Company Profile

SteadyMed Ltd. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of various therapeutic product candidates. Its primary focus is to obtain approval in the United States for the sale of Trevyent for the treatment of pulmonary arterial hypertension (PAH).

Earnings History for SteadyMed (NASDAQ:STDY)

Receive News & Stock Ratings for SteadyMed Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SteadyMed Ltd. and related stocks with our FREE daily email newsletter.